Tevogen, Inc. (TVGN)
7.30
-0.06
(-0.82%)
USD |
NASDAQ |
Sep 14, 10:14
Tevogen Shareholders Equity (Quarterly) : -8.889M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.889M |
| March 31, 2026 | -9.842M |
| December 31, 2025 | -8.235M |
| September 30, 2025 | -7.824M |
| June 30, 2025 | -9.485M |
| March 31, 2025 | -7.720M |
| December 31, 2024 | -6.674M |
| September 30, 2024 | -6.190M |
| June 30, 2024 | -7.634M |
| March 31, 2024 | -5.803M |
| December 31, 2023 | -94.43M |
| Date | Value |
|---|---|
| September 30, 2023 | 9.847M |
| June 30, 2023 | 10.13M |
| March 31, 2023 | 10.05M |
| December 31, 2022 | 342.08M |
| September 30, 2022 | 339.47M |
| June 30, 2022 | 337.85M |
| March 31, 2022 | 337.65M |
| December 31, 2021 | 337.67M |
| September 30, 2021 | 0.0136M |
| June 30, 2021 | 0.0137M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 4.728M |
| Total Liabilities (Quarterly) | 13.62M |
| Debt to Equity Ratio | -1.062 |
| Current Ratio | 0.3267 |
| Net Debt Paydown Yield | -3.84% |